Cite
HARVARD Citation
Cortellini, A. et al. (2020). Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Journal for immunotherapy of cancer. 8 (2), p. . [Online].